Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso Sells 1,526 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 1,526 shares of the stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $10.32, for a total transaction of $15,748.32. Following the transaction, the chief executive officer now owns 13,772 shares of the company’s stock, valued at approximately $142,127.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Precision BioSciences Trading Down 3.0 %

DTIL stock opened at $10.52 on Friday. Precision BioSciences, Inc. has a twelve month low of $8.25 and a twelve month high of $27.02. The firm’s fifty day simple moving average is $12.55 and its two-hundred day simple moving average is $11.80.

Precision BioSciences (NASDAQ:DTIL) last released its quarterly earnings results on Wednesday, March 27th. The company reported ($3.35) EPS for the quarter, missing analysts’ consensus estimates of $3.00 by ($6.35). Precision BioSciences had a negative return on equity of 204.66% and a negative net margin of 125.84%. The firm had revenue of $7.04 million for the quarter, compared to analysts’ expectations of $28.50 million. Analysts anticipate that Precision BioSciences, Inc. will post -3.93 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on DTIL. Guggenheim assumed coverage on shares of Precision BioSciences in a report on Tuesday, April 30th. They issued a “buy” rating and a $19.00 price target for the company. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Precision BioSciences in a research report on Wednesday, April 17th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Curi Wealth Management LLC lifted its stake in shares of Precision BioSciences by 42.0% during the 3rd quarter. Curi Wealth Management LLC now owns 339,801 shares of the company’s stock worth $116,000 after acquiring an additional 100,530 shares during the last quarter. Tejara Capital Ltd increased its stake in Precision BioSciences by 100.7% in the third quarter. Tejara Capital Ltd now owns 398,614 shares of the company’s stock worth $136,000 after purchasing an additional 200,000 shares during the period. Finally, Acadian Asset Management LLC lifted its position in shares of Precision BioSciences by 8.3% during the third quarter. Acadian Asset Management LLC now owns 3,148,243 shares of the company’s stock worth $1,073,000 after purchasing an additional 242,425 shares during the last quarter. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.